REGENXBIO (NASDAQ:RGNX) Cut to “D+” at TheStreet

REGENXBIO (NASDAQ:RGNXGet Rating) was downgraded by analysts at TheStreet from a “c” rating to a “d+” rating in a research report issued to clients and investors on Monday, TheStreetRatingsTable reports.

Other analysts have also issued research reports about the company. SVB Leerink dropped their price objective on REGENXBIO from $29.00 to $25.00 and set a “market perform” rating on the stock in a research note on Wednesday, March 2nd. Chardan Capital restated a “buy” rating on shares of REGENXBIO in a research note on Monday, April 11th. StockNews.com assumed coverage on shares of REGENXBIO in a research report on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research lowered shares of REGENXBIO from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Finally, Morgan Stanley raised their target price on shares of REGENXBIO from $50.00 to $51.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 23rd. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $45.88.

Shares of RGNX opened at $21.70 on Monday. The company’s fifty day simple moving average is $28.67 and its 200 day simple moving average is $29.66. REGENXBIO has a 1-year low of $19.07 and a 1-year high of $46.46. The company has a market cap of $935.92 million, a price-to-earnings ratio of 10.09 and a beta of 1.12.

REGENXBIO (NASDAQ:RGNXGet Rating) last announced its quarterly earnings data on Tuesday, March 1st. The biotechnology company reported $6.67 EPS for the quarter, beating analysts’ consensus estimates of $4.28 by $2.39. The company had revenue of $398.66 million during the quarter, compared to the consensus estimate of $255.76 million. REGENXBIO had a net margin of 21.38% and a return on equity of 17.92%. The company’s quarterly revenue was up 1759.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.24) EPS. On average, analysts predict that REGENXBIO will post -4.47 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of RGNX. Voya Investment Management LLC increased its holdings in shares of REGENXBIO by 1.2% during the third quarter. Voya Investment Management LLC now owns 26,186 shares of the biotechnology company’s stock worth $1,098,000 after purchasing an additional 314 shares during the period. New York State Teachers Retirement System raised its holdings in REGENXBIO by 0.9% in the 4th quarter. New York State Teachers Retirement System now owns 45,631 shares of the biotechnology company’s stock valued at $1,492,000 after acquiring an additional 400 shares in the last quarter. TD Asset Management Inc. lifted its position in shares of REGENXBIO by 2.2% during the 3rd quarter. TD Asset Management Inc. now owns 20,600 shares of the biotechnology company’s stock valued at $864,000 after acquiring an additional 435 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of REGENXBIO by 8.0% during the 1st quarter. Teacher Retirement System of Texas now owns 6,589 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 487 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in shares of REGENXBIO by 3.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 14,443 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 488 shares in the last quarter. 87.57% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile (Get Rating)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Recommended Stories

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.